柳氮磺胺吡啶合用丹参治疗炎症性肠病机制探讨

目的 研究炎症性肠病（IBD）患者的神经内分泌免疫网络的变化,分析柳氮磺胺吡啶（SASP）合用丹参治疗IBD的可能机制.方法 前瞻性选取63例IBD患者,按随机数字表法分成SASP、SASP＋丹参组及空白组,进行治疗前后疗效,外周T细胞亚群测定,血浆SP、VIP、SS含量测定,并对其结果进行统计学分析.结果 IBD活动期CD3^＋、NK细胞较健康人明显下降.SASP＋丹参治疗组,CD4＋、CD8^＋、NK、CD4＋/CD8^＋与空白组比较无统计学差异.IBD活动期血浆SP较健康人明显下降,血浆VIP、SS较健康人明显升高.SASP＋丹参治疗组,患者血浆SP、VIP、SS含量与空白组比较无统计学差异.结论 SASP＋丹参是通过影响T细胞亚群,影响胃肠神经肽的水平调节免疫反应,达到治疗IBD作用的.

Combination of SASP with Danshen in treatment of inflammatory bowel disease

Objective To evaluate the efficacy of SASP combined with Danshen injection in treatment of inflammatory bowel disease （IBD）. Methods Sixty three patients with IBD were randomly divided into three groups： SASP, SASP ＋ Danshen and control group, peripheral T-cell subsets were analyzed, plasma SP, VlP and SS were determined. Results CD3^＋, NK cells in IBD were decreased significantly compared with healthy controls. There were no significant differences in CD4^＋, CD8^＋, NK, CD4^＋ / CD8^＋ levels between SASP ＋ Danshen group and control group. Compared with healthy controls plasma SP levels in IBD were significantly decreased, while plasma VIP, SS levels were significantly higher. There were no significant differences in plasma SP, VlP, SS concentration between SASP ＋ Danshen group and the control group. Conclusion Combination of SASP with Danshen injection demonstrates a therapeutic effects in IBD which is associated with changes of T cell subsets and gastrointestinal neuropeptides.